Table 3 Meta-analysis of the association between C-159T polymorphism and CVD risk
From: Effect of CD14 polymorphisms on the risk of cardiovascular disease: evidence from a meta-analysis
Sub-group analysis | No of data sets | No of cases/controls | Allele model (T VS.C) | Dominant model (CC VS.TT + CT) | Recessive model (TT VS.CC + CT) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cases | Controls | OR (b95% CI) | POR | PH | OR (95% CI) | POR | PH | OR (95% CI) | POR | PH | ||
Overall | 13 | 4813 | 2852 | 1.009(0.941–1.082) | 0.854 | 0.078 | 1.049(0.936–1.176) | 0.41 | 0.164 | 1.009(0.900–1.132) | 0.878 | 0.324 |
Ethnicity | ||||||||||||
 East Asian | 6 | 834 | 886 | 0.881(0.723–1.075) | 0.212 | 0.066 | 1.120(0.888–1.413) | 0.34 | 0.109 | 1.198(0.974–1.474) | 0.087 | 0.327 |
 European | 6 | 3769 | 1734 | 1.039(0.953–1.132) | 0.387 | 0.717 | 0.923(0.806–1.058) | 0.249 | 0.488 | 0.962(0.832–1.113) | 0.602 | 0.751 |
 Indian | 1 | 210 | 232 | 1.249(0.958–1.628) | 0.101 | – | 0.718(0.445–1.160) | 0.176 | – | 0.734(0.479–1.125) | 0.156 | – |
Endpoint | ||||||||||||
 EH-LVH | 2 | 219 | 216 | 0.974(0.746–1.271) | 0.845 | 0.81 | 1.045(0.669–1.631) | 0.847 | 0.817 | 1.028(0.672–1.573) | 0.898 | 0.87 |
 EH-NLVH | 2 | 207 | 216 | 0.846(0.646–1.109) | 0.227 | 0.981 | 1.051(0.669–1.653) | 0.828 | 0.967 | 1.424(0.938–2.162) | 0.097 | 0.957 |
 CHD | 3 | 459 | 503 | 0.804(0.514–1.257) | 0.338 | 0.007 | 1.292(0.953–1.785) | 0.121 | 0.007 | 1.186(0.904–1.556) | 0.217 | 0.1 |
 AMI | 4 | 2989 | 1325 | 1.048(0.950–1.156) | 0.351 | 0.512 | 0.926(0.790–1.085) | 0.342 | 0.729 | 0.917(0.778–1.080) | 0.3 | 0.314 |
 MI | 2 | 939 | 592 | 1.109(0.952–1.293) | 0.184 | 0.664 | 0.817(0.642–1.038) | 0.098 | 0.669 | 0.957(0.735–1.246) | 0.743 | 0.851 |